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Abstract
Chemical Imaging (CI) is an emerging platform technology that integrates
conventional imaging and spectroscopy to attain both spatial and spectral information
from an object. Vibrational spectroscopic methods, such as Near Infra Red (NIR) and
Raman spectroscopy, combined with imaging are particularly useful for analysis of
biological/pharmaceutical forms. The rapid, non-destructive and non-invasive features
of CI mark its potential suitability as a process analytical tool for the pharmaceutical
industry, for both process monitoring and quality control in the many stages of drug
production. This paper provides an overview of CI principles, instrumentation and
analysis. Recent applications of Raman and NIR-CI to pharmaceutical quality and
process control are presented; challenges facing CI implementation and likely future
developments in the technology are also discussed.
Keywords: chemical imaging, non-destructive, pharmaceutical, drug, Raman, NIR
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1.

Introduction

The US Food and Drug Administration (FDA)-led process analytical technology
(PAT) initiative is transforming approaches to quality assurance in the pharmaceutical
industry. Core to the PAT initiative is increased process understanding by monitoring
of critical performance attributes, leading to better process control and ultimately
improved drug quality [1]. Potential advantages of PAT implementation include:
reduced production cycle times, prevention of rejects, reduction of human error and
facilitation of continuous processing to improve efficiency. With adequate knowledge
of the ingredient-process relationship, the FDA will allow a pharmaceutical company
to adjust their manufacturing process to maintain a consistent output without
notification to the FDA [2].The real time release paradigm assures that when the last
manufacturing step is passed, all final release criteria are met [3]. Adoption of such a
quality by design approach would allow significant benefits to be gained by
pharmaceutical companies: labour and time intensive finished product testing would
be avoided if the product could be released based on in-process data. This possibility
is driving pharmaceutical companies to gain a more complete understanding of their
processes and input variable relationships to realise the benefits of PAT registrations.

Process monitoring and control are necessary at all stages of pharmaceutical
processing, from raw material to packaged product characterisation. Traditional
quality control methods such as High Performance Liquid Chromatography (HPLC)
and Mass Spectroscopy (MS) are time consuming, destructive, expensive, require
lengthy sample preparation and give no information about the distribution of
components within a sample. Due to the destructive and time consuming nature of
these methods, only small samples of drugs may be tested from given production
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batches [4]. Motivated by the PAT initiative, pharmaceutical analytical techniques are
being developed to provide real-time process control to improve understanding of the
chemical and physical processes that occur during pharmaceutical unit operations.
Vibrational spectroscopic techniques such as Near infrared spectroscopy (NIRS) and
Raman spectroscopy (RS) have emerged as valuable tools for pharmaceutical quality
analysis.

NIRS is widely recognised as a valuable tool in pharmaceutical analysis for raw
material testing, quality control and process monitoring, mainly due the advantages it
allows over traditional methods, e.g. speed, little/no sample preparation, capacity for
remote measurements (using fibre optic probes), prediction of chemical and physical
properties from a single spectrum [5] and [6]. Räsänen and Sandler [7] provide a
comprehensive review on the applications of NIRS in the development of solid
dosage forms, documenting the usefulness of this technique for each of the
manufacturing steps, from raw material screening to assessment of the final dosage
form. Reich [5] reviewed the regulatory status of NIR analysis in the pharmaceutical
industry, noting that although many pharmaceutical companies have successfully
implemented NIR systems in QC labs for raw material identification and
qualification, only a few quantitative NIR methods have yet gained regulatory
approval.

Raman spectroscopy (RS) is based on the Raman effect: a substance, when irradiated
with monochromatic light, scatters most of it at the incident frequency, but a small
proportion of photons (0.0001%) are scattered with shifted frequency; the inelastic
scattering of a photon which creates or annihilates an optical phonon is known as the
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Raman effect. RS is highly selective; Raman spectra are more distinct and less
overlapped than NIR spectra. Low signal to noise ratio is, however, a problem for RS,
which arises due to the very small proportion of scattered photons that make up the
Raman signal, and the need to use filters to remove the excitation line from the
collected radiation [8]. The high cost of instrumentation has acted as a barrier to its
routine industrial utilisation, nonetheless, the value of Raman spectroscopy in
pharmaceutical analysis is well recognised; Rantanen [8] recently published a review
documenting the process analytical applications of RS in the area of pharmaceutical
dosage forms. Its potential application in dosage formulation, from chemical synthesis
to tablet coating were described, along with a discussion of the main challenges facing
its implementation in process analysis, which include: interfacing with process
environment, sample heating during measurement and small sampling area.

Spectrometers integrate spatial information to give an average spectrum for each
sample studied. The inability of NIR and Raman spectrometers to capture internal
constituent gradients within samples may lead to discrepancies between predicted and
measured composition. Furthermore, point-source spectroscopic assessments do not
provide information on spatial distribution of different constituents, which is
important in many pharmaceutical applications such as blending.

Chemical Imaging (CI) is an emerging technique that integrates conventional imaging
and spectroscopy to attain both spatial and spectral information from an object. The
terms Spectral and Chemical are often interchanged to describe this type of imaging:
Spectral Imaging is an umbrella term that can be applied to almost any optical
spectroscopic technique (e.g. IR, Raman, Fluorescence, UV), while Chemical Imaging
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refers to the vibrational spectroscopies (IR, NIR, Raman). By combining the chemical
selectivity of vibrational spectroscopy with the power of image visualisation, CI
enables a more complete description of ingredient concentration and distribution in
inhomogenous solids, semi-solids, powders, suspensions and liquids. Another major
advantage of CI is that, unlike traditional spectroscopic methods, separate
classification standards are not required. The large number of individual spectra
acquired across the spatial dimension of heterogeneous compounds provides a basis
from which relative concentrations can be determined for each spatial location. Some
features of CI are compared with NIRS and RS in Table 1.

One of the earliest papers concerning CI [9] reported its application for identification
of chemical constituents of wheat. Technology has advanced since then; CI can now
be implemented on the processing line. Industrial applications of NIR-CI include inline sorting of paper [10], real time quality control during andalusite production [11]
and on-line classification of synthetic polymers [12]. There have been many
publications documenting the utilisation of CI in medical diagnostics [13], [14] and
[15]. However, it is still emerging as a tool for analysis of pharmaceutical processes
and formulations. This review is structured to provide an overview of the principles,
instrumentation and analytical techniques involved in Chemical Imaging, followed by
a review of the recent applications of NIR-CI and Raman-CI to pharmaceutical
process monitoring and quality control. Current challenges facing CI and likely future
developments in the technology are also presented.

2.

Principles of Chemical Imaging
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Chemical Images are made up of hundreds of contiguous wavebands for each spatial
position of a target studied. Consequently, each pixel in a Chemical Image contains
the spectrum of that specific position. The resulting spectrum acts like a fingerprint,
which can be used to characterise the composition of that particular pixel. Chemical
Images, known as hypercubes, are three dimensional blocks of data, comprising of
two spatial and one wavelength dimension, as illustrated in Figure 1. The hypercube
allows for the visualization of biochemical constituents of a sample, separated into
particular areas of the image, since regions of a sample with similar spectral
properties have similar chemical composition.

It is currently unfeasible to obtain information in all three dimensions of a hypercube
simultaneously; one is limited to obtaining two dimensions at a time, then creating a
three dimensional image by stacking the 2 dimensional ‘slices’ in sequence. There are
two conventional ways to construct a hypercube. One method involves acquisition of
simultaneous spectral measurements from a series of adjacent spatial positions - the
object is moved underneath an imaging spectrograph in what is known as pushbroom
acquisition [16]. This method has been applied for hypercube acquisition in Raman
mapping investigations [17] and [18]. Another method involves keeping the image
field of view fixed, and obtaining images one wavelength after another in what is
known as a staring imager configuration [5]. This method has been popular for
construction of NIR-CI hypercubes in pharmaceutical applications [19] and [20].

3.

Chemical Imaging instrumentation

Instrumentation for acquisition of Chemical Images varies from lab to lab: some
research facilities have built their own instruments; others have purchased
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commercially available complete systems. The two main types of Chemical Imaging
system are discussed here, namely staring imager and pushbroom configurations.
Both configurations are applicable to both Raman and NIR imaging; although, as
previously mentioned, the staring imager configuration is commonly applied to NIRCI investigations, while the pushbroom system is more typically applied to Raman
mapping experiments. While the components of these systems vary, they can be
schematically represented as in Figure 2. The following general components are
usually required: illumination source, imaging optic, spectral encoder for wavelength
selection, detector and acquisition system (usually a frame-grabber board interfaced
with a PC). Advances in the production of low cost array detectors have meant faster
data collection and cheaper Chemical Imaging systems; detection time depends on
spatial and spectral resolution required, increasing with increasing resolution.

3.1

Pushbroom Acquisition

Pushbroom imaging systems require a translation stage for sample movement. Some
Raman mapping instruments produce Chemical Images using an optical microscope
coupled to a spectrometer [21]. These instruments are based on step and acquire
acquisition mode: spectra are obtained at single points on a sample, then the sample is
moved and another spectrum taken. This process is repeated until spectra of points
spanning the entire sample are obtained. Advances in detector technology have
reduced the time required to acquire Chemical Images. Raman line mapping
experiments are also possible [22], where the spectrum of each pixel in a line of
sample is simultaneously recorded by an array detector. In Raman mapping the
sample is usually illuminated by a laser source in the visible or NIR wavelength
range. A line of light reflected from the sample enters the imaging optic (usually a
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microscope lens) and is separated into its component wavelengths by diffraction
optics contained in the spectral encoder, which is usually a spectrometer in point
mapping systems and a spectrograph in line mapping systems; a two-dimensional
image (spatial dimension x wavelength dimension) is then formed on the detector.
The sample is moved past the objective lens on a motorized stage and point or line
images acquired at adjacent points on the object are stored on a PC for further
analysis. Charge Coupled Device (CCD) detectors (sensitive between 400-1000 nm)
are typically used as detectors in Raman imaging, while Fourier Transform (FT)
Raman imaging systems require more expensive longer-wavelength focal-plane array
(FPA) detectors [21].

3.2

Staring Imager Configuration

The major advantage of this method over the pushbroom technique is that it doesn’t
require any moving parts.The sample is usually illuminated with a diffuse source of
NIR light (for NIR-CI) or dilated laser source (for global Raman Imaging). Light
reflected from the sample is captured via an imaging optic; for microscopic images a
microscope objective lens is used. The light is then passed through a filter, which acts
as a spectral encoder in this arrangement, separating images into their spectral
components. Early staring configuration Chemical Images were obtained using a
series of bandpass filters selective to certain wavelengths of light, which were often
mounted on a wheel for ease of switching. Recent advances in tunable filters, which
can select wavelengths rapidly through software control, have rendered the time
consuming bandpass method largely obsolete. Acousto-optic Tuneable Filters
(AOTFs) and Liquid Crystal Tuneable Filters (LCTFs) are the two most widely used
tuneable filters in CI. AOTFs have been used in the construction of commercially
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available NIR-CI systems [23], while LCTFs show greater promise for filtering of
Raman images [21]. After spectral encoding, an image of the sample at the selected
wavelength is recorded on a detector, which is usually a CCD detector for Raman
Imaging and an FPA for NIR Imaging. Images at subsequent wavelengths are stacked
to form a hypercube and stored on a PC for further analysis.

4.

Chemical Image analysis

Chemical Image files are typically immense; for example, a hypercube with spatial
dimensions of 256 x 256 pixels operating at 150 wavebands contains more than
65,000 spectra, each with 150 data points. In attempting to extract useful information
from such information-dense datasets a multidisciplinary approach is required,
involving advanced image processing and multivariate statistical methods. Numerous
techniques exist to mine the chemical, physical and spatial information hidden in
Chemical Images. The challenge is to reduce the dimensionality of the data while
retaining important spectral information with the power to classify important areas of
a sample effectively. Typical steps involved in analysing Chemical Images are
outlined in Figure 3 and described below.

4.1

Reflectance Calibration

This is carried out to account for the background spectral response of the instrument
and the ‘dark’ camera response. For reflectance measurements, the background is
obtained by collecting a hypercube from a uniform, high reflectance standard or white
ceramic; the dark response is acquired by turning off the light source, completely
covering the lens with its cap and recording the camera response. The corrected
reflectance value (R) is calculated as follows:
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R = (sample – dark)/(background-dark)

4.2

Pre-processing

Pre-processing is usually performed to remove non-chemical biases from the spectral
information (e.g. scattering effects due to surface inhomogeneities, interference from
external light sources, random noise) and prepare the data for further processing.
Mathematical treatments to compensate for scatter-induced baseline offsets include
multiplicative scatter correction, Savitzky-Golay derivative conversion and standard
normal variate correction. Normalisation algorithms can be used to compensate for
baseline shifts and intensity variations resulting from path length differences. Other
operations usually carried out at the pre-processing stage include thresholding and
masking to remove redundant background information from the hypercube.

4.3

Classification

Hypercube classification enables the identification of regions with similar spectral
characteristics, providing information on the physical and chemical properties of a
sample, their distribution and concentration. Due to the large size of hypercubes
(which can exceed 50 MB, depending on image resolution, spectral resolution and
pixel binning) complex multivariate analytical tools are usually employed for
classification. Analysis of each spectrum in a hypercube can be performed with
chemometric tools designed for bi-linearly structured data sets. In order to apply
conventional chemometric techniques in Chemical Image analysis, it is necessary to
restructure the hypercube: in a process known as spectral unfolding the 3-dimensional
hypercube is rearranged into a 2-dimensional matrix, by appending the two spatial
dimensions. After classification, the image matrix is folded back into 3-dimensional
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form from which Chemical Images are produced.Unsupervised classification
methods, such as principal component analysis (PCA), k-means clustering and fuzzy
clustering, require no apriori information about the dataset, and are useful as
exploratory tools to extract important features. Supervised techniques, such as partial
least squares (PLS), linear discriminant analysis (LDA), Fishers discriminant analysis
(FDA) and artificial neural networks (ANN), require prior knowledge about the data
and selection of pre-defined training sets against which to classify the data. Training
sets can be selected from regions of the hypercube using previous knowledge of
sample composition. Another approach involves selection of training sets from areas
identified by the unsupervised analyses as containing a specific component;
combining unsupervised and supervised methods in this way provides a means of
locating constituent components without apriori knowledge of the sample.

4.4

Image processing

Image processing is carried out to convert the contrast developed by the classification
step into a picture depicting component distribution. Greyscale or colour mapping
with intensity scaling is commonly used to display compositional contrast between
pixels in an image. Single wavelength images are easy to produce but can be
misleading, since the depicted images may be biased or dominated by variations in
thickness across sample surface; multi-wavelength images give a better representation
of the sample composition [24]. Image fusion, in which two or more images at
different wavebands are combined to form a new image [25] is frequently
implemented to provide even greater contrast between distinct regions of a sample.
Images may be combined using algorithms based on straightforward mathematical
operators, e.g. addition, subtraction, multiplication and division. One example is the
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band ratio method, in which an image at one waveband is divided by that at another
wavelength [26] and [27]. Histograms are another tool, useful for depicting pixel
distribution of components.

5.

Pharmaceutical Applications

5.1

NIR Chemical Imaging

NIR Chemical Imaging (NIR-CI) has been applied to a number of process and quality
related investigations for pharmaceutical products, including quality assessment, highthroughput

analysis,

coating

thickness,

compositional

information,

remote

identification, blend homogeneity, extraction of process related effects and counterfeit
drug identification. Table 2 presents a summary of the published applications of NIRCI to pharmaceutical analysis since 2001. The following sections describe each
application in more detail.

5.1.1

Quality assessment

Westenberger et al. [30] compared quality assessment of pharmaceutical products
purchased via the internet using a variety of traditional (HPLC-based) and nontraditional (NIR, NIR-CI) techniques. A staring imager chemical imaging system was
utilised to obtain Chemical Images of individual specimens at 121 wavelengths
between 1050 – 1700 nm. The NIR-CI technique had an added advantage over
traditional techniques in its ability to detect suspect manufacturing issues, such as
blending and density pattern distribution of components within a drug product,
allowing direct qualitative comparison with control products. It was also noted that
the NIR and NIR-CI techniques are non-destructive so that defective samples could be
scanned and saved for further testing.
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Another paper reports the utilisation of NIR-CI for qualitative analysis of
pharmaceutical forms [20]. A microscope coupled with a FPA detector constituted the
NIR Chemical Imaging system in this case. Peak wavelength height and Principal
Component Analysis (PCA) were used for qualitative analysis of surface
contamination on solid dosage forms and to identify dissolution properties of a
number of samples. While NIR imaging alone was sufficient for describing
dissolution problems, imaging combined with PCA was necessary for identifying
contamination.

5.1.2

High throughput analysis

The huge volume of production encountered in the pharmaceutical industry
necessitates high throughput quality analysis techniques. NIR-CI may be adapted to
perform analysis on multiple samples in a single field of view by increasing the
distance between the camera and target. Fast and nondestructive identification of
active ingredients and excipients in whole tablets can be achieved, even through
packaging [38] and [39]. A paper published in 2001 [40] reported the use of
multispectral imaging for simultaneous identification and composition of multiple
individual tablets in blister packaging. A FPA interfaced with a tuneable interference
filter was used to obtain images of 1286 tablets in blister packs at wavelengths in the
range 1678-2312 nm. It was stated that multispectral imaging offers a potential speed
advantage of approximately 30,000 over HPLC when determining moisture and
salicylic acid content in single packaged aspirin tablets, and that NIR-CI is up to 1000
times faster than NIRS of single tablets. Hamilton & Lodder [38] reported that a
typical NIR chemical imaging system could simultaneously analyse around 1300

15

tablets in blister packaging. A more recent paper [39] reported high throughput
analysis of pharmaceutical tablet content uniformity using NIR-CI. A large field of
view NIR-CI device was used to take simultaneous Chemical Images of 20 tablet
samples at 61 wavelengths. The total time for image acquisition was less than 2 min,
while the conventional UV method took approximately half a working day for sample
analysis.

It was observed that the mean intensity of images at 1600 nm was

proportional to active pharmaceutical ingredient (API) concentration; the authors
suggested that a multispectral instrument based on a small number of wavelengths
around 1600 nm could be built to rapidly identify API concentration of these tablets in
packaged form.

5.1.3

Coating Thickness

Lewis, Kidder & Lee [35] applied NIR-CI for quantification of coating thickness in a
single time release micro-sphere. NIR Chemical Images demonstrated the differences
in chemical structure of the tablet core and coating, enabling quantitative information
on coating thickness and homogeneity to be determined. Uneven coating could be
clearly identified by visualisation of the total intensity image at 2080 nm. A group of
135 microspheres containing two different microsphere types was also imaged in this
study. Discrimination of microsphere type was readily visualised in a spectral
difference image.

5.1.4

Compositional Information

Many new drug release systems require complex tablet architecture. In 2001, Lewis,
Carroll & Clark published a paper [28] showing how NIR-CI could be employed for
qualitative description of composition and architecture of a solid dosage form. A time-
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release granule was bisected and an NIR-CI system was used to acquire Chemical
Images at 71 wavelengths from 1000 to 1700 nm in approximately 2 min.
Unsupervised PCA was used to identify spatial and chemical variance in the sample.
Loading scores of the principal components were used to produce score images of the
sample which clearly showed boundaries in the sample where chemical composition
varied.

5.1.5

Remote identification

Hamilton & Lodder [38] investigated the potential implementation of a far field
imaging system to identify pharmaceutical capsules. Individual gelatin capsules,
subjected to degradation by exposure to formaldehyde, were imaged from a distance
of 500 m using a telescopic lens interfaced with a NIR imaging system. Images were
only collected at 6 wavelengths to reduce data collection time. Principal component
regression of the spectra against time of exposure to formaldehyde gave promising
results (r2 = 0.89, SEP = 1.17 h). Similar results were published in another paper [41].

5.1.6

Blend Uniformity

Powder blend homogeneity in final dosage product poses a significant problem in
pharmaceutical quality assurance; poor blending tends to adversely affect tablet
hardness, appearance and dissolution kinetics. Lyon et al. published a paper in 2002
[33] comparing the ability of NIR-CI and NIRS in distinguishing blending grade for a
selection of final dosage forms. Individual tablets with different blending grades were
imaged at 71 wavelengths from 1000-1700 nm using a staring imager configuration
Chemical Imaging system. PLS was employed for hypercube analysis. While NIRS
was limited in its ability to evaluate drug product homogeneity, NIR-CI provided the
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opportunity to investigate localised micro-domains of ingredients within a drug. It
was noted that physical and chemical abnormalities that made minimal contribution to
the bulk tablet would be undetected by traditional NIRS but detected by NIR-CI.

More recently, the US FDA has embarked on an industrial collaborative project which
aims to develop Chemical Imaging instrumentation for blend process monitoring [42].
A prototype instrument, the Blend Monitor (see schematic in Fig. 4) has been
designed for application of NIR Chemical Imaging at a process scale. This instrument
is based on a LCTF staring imager configuration; a fibre optic bundle is interfaced
with the blender to collect and transmit NIR spectral information from the blend to the
NIR imaging spectrometer [34]. The instrument thus records Chemical Images of
samples inside the blender. However, rotation of the blender is problematic as the
Blend Monitor cannot co-rotate, requiring the blender to be stopped before
measurement. Therefore, this instrument cannot currently be used “in process” for
online measurements.

5.1.7

Process Related Information

Pharmaceutical products undergo various chemical and physical changes during
processing. Characterising the nature and sources of these changes is a major
challenge for PAT. Clarke [31] reported the utilisation of NIR-CI microscopy for
identification of tablets which experienced problems during processing and for
investigation of pre-tabletting blends with dissolution issues. Chemical Images of
samples were obtained at 121 wavelengths between 1100 – 1700 nm. PCA was
performed on the Chemical Images of tablets which experienced problems during
processing; image reconstruction was achieved using PCA scores and loadings. PLS
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classification was used for the pre-tabletting blends with dissolution issues; cluster
size of ingredients was measured to investigate the effect of compaction force on
dissolution properties. In a similar study, the potential of NIR-CI for investigating the
effects of processing on tablet dissolution was examined [32]. It was shown that NIRCI could be used for the prediction of coating time and to understand batch
differences due to different processing conditions.

5.1.8

Counterfeit Drug Identification

The problem of counterfeit drugs is widespread; so-called “high-quality” counterfeit
drugs are difficult to detect. Rodionova et al. [36] reported advances in the feasibility
of detecting counterfeit drugs using both NIRS and NIR-CI. Chemical Images were
obtained for two tablet powder samples at 128 wavelengths in the range 900 – 1700
nm. PCA was applied for image analysis, and clustering evident in the score plot of
the first and third principal components was related to drug composition. The authors
remarked that NIR-CI is useful for identifying small differences in ingredient
distributions, which is important for identification of so-called “high quality”
counterfeit samples. A similar study reported the use of NIR-CI in the analysis of
multiple samples to discriminate between counterfeit and non-counterfeit tablets
without prior knowledge of sample architecture or composition [37].

5.2

Raman Chemical Imaging

Raman Chemical Imaging has been applied to many diverse fields, including polymer
classification [43], dental sample characterisation [44], process monitoring of
semiconductors [45] and detection of filtered waterborne bacteria [46]. A large
number of patents for Raman Imaging applications exist, including one describing the
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application of Raman imaging microscopy for the evaluatation of drug action within
living cells [47]. In most Raman Imaging experiments, a microscope is attached to the
imaging system to enable molecular characterisation. Some recently published
applications of Raman spectroscopy in pharmaceutical analysis, summarised in Table
3, include minor component detection, detection of process related effects, particle
size estimation and tablet characterisation. These applications are discussed in more
detail in the following sections.

In simple cases Raman imaging can provide data on API distribution within tablets in
a very straightforward fashion. For example, Figure 5 shows a composite Raman
image comparing data from two tablets (half of each is shown to highlight the
differences) with the same overall composition but different formulation protocols.
These pushbroom images were recorded at 100 µm micron spacing on a 70/70 grid
i.e. a total scan area 7 mm square to allow the entire face of each tablet to be imaged.
Accumulation time was 5 s per point, leading to a total acquisition time of
approximately 7 h. Both tablets were prepared from mefenamic acid (API) (20% by
mass) with Lutrol binder and lactose bulking agent. In one case the constituents were
prepared by normal co-melt fluidised bed granulation i.e. the three constituents were
granulated in a fluidised bed whose temperature was taken above that of the melting
point of the binder. The solubility of this API in the Lutrol binder is relatively low,
which leads to non-uniform distribution in the granules and ultimately the tablets
prepared from them, as shown in the Figure. The corresponding image with higher
uniformity of colour is one where the API was first dissolved in binder and the
resulting mass reground before being granulated in a fluidised bed as before. This
procedure improves the uniformity of API distribution in the granules and the tablets
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prepared from them. There are numerous ways to treat these data, such as plotting the
relative band intensities of the API and binder/excipient. However, in these images
the data at each pixel were compared to a standard (average) spectrum of a sample
which had API and binder/excipient band intensities at the desired level by calculating
a simple correlation coefficient. In these images the positions where the correlation
was high are white/pink while positions where there is poorer correlation are
green/blue. The spectra at the areas showing blue are essentially pure API, as
evidenced by comparison of spectra obtained at these positions with that of a pure
API standard.

5.2.1

Minor component detection

Many new drugs contain small concentrations of potent APIs delivered by complex
delivery systems. It is imperative that content uniformity can be maintained in such
systems. Šašic [49] published a study on Raman Chemical Imaging of low content
API pharmaceutical formulations in which Raman maps were obtained from the
flattened surfaces of 6 tablets using a pushbroom Raman Imaging system. Univariate
images, produced from the intensity recorded at each pixel at individual wavelengths
were difficult to interpret, and the author reported that reliable API Raman signal was
only detected upon applying Principal Component Analysis (PCA) to the data.

Šašic & Clark [22] investigated the performance of Raman line-mapping compared
with global illumination Raman systems for the analysis of tablets and formulation
blends. A pushbroom configuration was used in the line-mapping experiment, while a
staring imager configuration was used in the global experiment. Raman line-mapping
technology was demonstrated as preferable for identifying minor components in
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samples, whereas the global illumination system was recommended for imaging of
spatially isolated strong Raman scatterers. These researchers also reported a novel
chemometric technique for analysis of Raman Images of pharmaceutical samples [53].
This method, called sample-sample two dimensional correlation, involves analysis of
the covariance matrix of the Raman mapping spectral matrix. The most unique spectra
in the mapping matrix are identified by analysing the slices of the covariance matrix
at positions where the covariance values are maximum; Chemical Images are then
produced by visual selection of the wavenumbers in the extracted spectra that are least
overlapped. The authors demonstrated that this method was suitable for producing
reliable images of unknown samples of pharmaceutical tablets containing up to 4
active components.

5.2.2

Extraction of Process Related Effects

Henson & Zhang [18] published an article on drug characterization of low dosage
pharmaceutical tablets using Raman microscopic mapping. Raman Images were
obtained using a Raman line-mapping instrument. Domain size and spatial
distribution of the API and major excipients were estimated from Raman maps of the
tablets. It was demonstrated that domain size of the API was dependent upon the
particle size distribution of the ingoing API material; therefore, the Raman maps
could be used to indicate the source of API used in tablet manufacturing. The
potential utility of Raman microscopic mapping in manufacturing process
optimization or predictive stability assessments was also outlined.

5.2.3

Particle size estimation
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Doub et al. [48] reported the application of Raman-CI for ingredient specific particle
size characterisation of nasal spray formulations. Samples of aqueous suspension were
sprayed onto inverted aluminium-coated glass microscope slides and allowed to dry
before imaging. A Raman Imaging particle size distribution (PSD) protocol was
developed and validated using polystyrene (PS) miscrosphere size standards. Good
statistical agreement was obtained between reported PS particle sizes and those
estimated using Raman-CI. Moreover, Raman–CI was suitable for distinguishing
between active samples and placebos. It was noted, however, that vigorous validation
of Raman-CI for PSD is required, due to the high variability associated with replicate
measurements.

5.2.4

Tablet characterisation

Šašic [29] published findings from a study in which Raman-CI was compared with
NIR-CI for determining spatial distribution of multiple components in tablets.
Multivariate Raman images could identify all of the components in each tablet
studied, while only two or three components could be imaged using NIR imaging. It
was demonstrated that the eigenvalue-based criteria for choosing principal
components was ineffective for these Raman Chemical Images, and the author
remarked that the basic postulates of PCA could pose a significant problem when
applied to Raman mapping spectra. For NIR mapping spectra, interpretation of PCA
proved difficult; problems were associated with associating pure component spectra
and loadings. It was demonstrated that PCA was less efficient for producing NIR-CIs
than for Raman CIs.
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Raman Chemical Imaging in conjunction with multivariate statistical analysis enables
the extraction of information about the concentration and distribution of pure
compounds in a sample. A paper published in 2004 [52] elucidated a multivariate
approach to both global and local Chemical Imaging and tested the proposed
methodology on Raman images of tablets. Five tablets, each with varying amounts of
API and excipient, were imaged using a Raman point mapping system with 45 x 45
grid points and 576 wavelengths between 8525-16420 nm. Global Principal
Component Analysis (PCA) was applied to the entire data set to determine the number
of compounds present. This was followed by local PCA, applied sequentially to small
subsets of the data, to examine the distribution of compounds in the individual tablet
samples. An interative optimisation approach was employed to minimise model error.

Zhang, Henson and Sekulic [54] reported on the merits and drawbacks of applying a
selection of multivariate data analysis techniques (PCA, cluster analysis, direct
classical least squares (DCLS) and multivariate curve resolution (MCR)) for
analysing Raman images of a model pharmaceutical tablet. Raman maps were
obtained using a microscopic Raman line-mapping instrument. It was noted that,
although PCA was effective for exploratory data analysis, there was generally no oneto-one correspondence between PCs and a chemical components. The potential use of
cluster analysis as a tool for automatic segmentation of images enabling visualisation
of distinct regions with similar chemical composition in drugs was also described; this
method would be particularly valuable for characterisation of solid dosage with
distinct spatial distribution character, such as controlled release formulations.
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Bell et al. [51] , [55], [56] and [57] published findings on the development of
quantitative analytical methods for Raman analysis of solid dosage forms. In one
paper, this research team reported results on Raman mapping of seized ecstasy tablets
[51]. Raman point mapping was performed on tablet samples on both microscopic and
macroscopic scales to investigate the effects of sampling size on measurement error.
Micro-Raman mapping was achieved using a Raman microscope with a motorised x-y
translation stage, and macro-Raman maps were obtained using a Raman spectrometer
with an x-y-z stage. Figure 6 shows a coarse Raman map of the peak area of the
strongest MDMA band in the Raman spectra of a seized ecstasy tablet, taken at 785
nm with a Raman microscope (8 x 8 grid, 10 µm spacing, 50x objective lens).
Although only a small number of grid points were measured (to decrease time and
cost of analysis), inhomogeneous distribution of tablet components (MDMA, caffeine
and lactose) is evident. It was demonstrated that acceptably low sampling errors could
be achieved when less than 100 points were sampled, and that sampling error could
be estimated by comparison of sub-sets of data in the grid. It was reported that for the
macro-Raman system, grid acquisition time of 1 min for individual tablets could
potentially be realised.

Another more recently published article discusses the impact of spatial sampling
density in Raman Imaging [50]. In this investigation, Raman point mapping was
applied to a fixed (magnified) area of an over-the-counter drug using spatial steps
ranging from 10 to 100 µm. The coarse grid (with 100 µm steps) Raman image took a
few minutes to acquire, while the fine grid (with 10 µm steps) took several hours to
record. It was demonstrated that the coarse measurement could be useful for selection
of regions which required further fine measurement. Although the fine grid method is
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time consuming, it would allow for visualisation of the chemical distribution of the
sample with details of crystal morphology.

6.

Challenges

The potential applications of Chemical Imaging for pharmaceutical process
monitoring and quality analysis have been highlighted in this article. Nevertheless, it
is worthwhile to note that Chemical Imaging is not an end-all solution for
pharmaceutical analysis. For many applications, single point spectroscopic methods
are sufficient (e.g. for bulk sample identification or quantitative determination of the
average composition of a substance). On the other hand, there remain key areas in
pharmaceutical process monitoring for which CI is quite possibly the best solution,
i.e. measuring spatial heterogeneity, component distribution, coating thickness,
particle size, contaminant detection and high throughput analysis. However, the
technology is not without its limitations; some challenges face the routine
implementation of CI in the pharmaceutical industry and are explored below.

6.1

Chemometrics

Šašic [29] reported that using PCA on both Raman and NIR spectra of pharmaceutical
tablets led to problems associated with associating pure component spectra and
loadings. Some authors have remarked that conventional chemometric methods such
as PCA and PLS may not be suitable for analysing Chemical Images, since these
techniques were developed for analysing single spectra [58] and [59]. To overcome
the limitations of conventional chemometric approaches, a number of novel
chemometric methods have been proposed. One example is support vector machines
(SVMs). SVMs belong to the group of machine learning algorithms that use
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optimization tools, which work to identify the optimal hyperplane as a decision
surface to discriminate between classes of interest. These chemometric tools are
rapidly emerging as superior tools for a diverse group of pattern recognition and
classification applications [60] and [61]. The application of novel chemometric
techniques such as SVMs in CI for pharmaceutical analysis may result in improved
detection capability.

6.2

Raman Global Imaging

In the majority of published research on Raman Imaging (Table 3), hypercubes are
acquired by means of point or line mapping. Šašic [29] stated that “line-mapping
systems are more widely understood and are more frequently used in practise”.
However, Schlucker et al. [62] reported that higher spatial resolution is obtained from
global Raman Imaging than point or map Raman Imaging, and this enables subtle
morphological features on test samples to be imaged. Moreover, Raman line and point
mapping experiments can be painfully time consuming (up to 20 h). Raman global
imaging experiences difficulties when a large field of view is required, since it is
difficult to flood these areas with laser power [63]. Another problem that may arise
from the wide field illumination required in global Raman imaging is spectral
averaging due to photon migration [28]. It is clear that these challenges need to be
overcome in order to realise the full benefits of global Raman Imaging as a PAT tool.

6.3

Image acquisition time

A major factor limiting the implementation of CI for routine process monitoring arises
from the relatively lengthy times necessary for hypercube image acquisition
processing and classification [64]. Depending on target size, image and spectral
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resolution required, acquisition time can range from 2 - 4 min (some Raman mapping
experiments require up to 20 h acquisition time), while processing and classification
time are largely dependant on computer hardware and software capabilities. However,
it can be expected that future developments in the technology will shorten processing
and acquisition time, enabling real-time CI process monitoring systems. Chemical
Image Fusion, discussed in the next section, is a promising technique for reducing
processing time in CI.

7.

Future prospectives

Future improvements in precision and speed in Chemical Imaging are likely to arise
with increased computer processing speeds, improved cameras, faster hardware, more
accurate and efficient algorithms. Further applications of this emerging technique to
pharmaceutical product quality and process monitoring will certainly arise with the
development novel solutions for online data acquisition and more powerful data
evaluation strategies. A selection of novel technologies related to Chemical Imaging
are discussed in the following sections.

Chemical Image Fusion is a technique proposed by Clarke et al. [65] to exploit the
complementary benefits of NIR and Raman microscopy. Raman and NIR Chemical
Images from the same area of a target are acquired, giving rise to a combined
Chemical Image that visually describes the entire formulation. In Clarke’s study,
combined images of pharmaceutical samples were obtained by merging Chemical
Image maps of samples obtained from separate FT-NIR and Raman instruments.
Reference marks were used to ensure that the same area was imaged on each
instrument. Peak area measurements of baseline corrected single spectroscopic bands
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which were unique to the different sample components were used to generate images
of each sample for particle size and distribution analysis. As instrumentation and
chemometric methods to process this type of data are developed, it is likely that
Chemical Image Fusion will find wider application in the field of pharmaceutical
analysis

An exciting new technique, known as Integrated Chemical Imaging (ICI), has been
proposed to reduce the data load and increase processing speed in Chemical Imaging
[66]. Innovative spectrometer designs have been developed that speed up the process
by enabling the sensing detector to do some of the computation. Once a set of training
spectra at all available wavelengths has been accumulated, it is possible to rationally
select molecular filter (MF) materials to perform PCA on the incoming data by
weighting signals from spectral regions with most variability. Integration of such
selective molecular filters (MF) with detectors would enable molecular computing to
replace traditional chemometric methods, e.g. PCA. This is the same as physically
implementing chemometric calculations in spectroscopic systems [67]. Rapid analysis
coupled with reduced data storage requirements indicate that the practical realisation
of ICI systems as PATs is not far away.

In a recent paper on future outlook for NIR-CI instrumentation, Bellon-Maurel [68]
stated that imaging systems based on electronically tuneable filters (AOTF & LCTF)
rather than filter-based or pushbroom systems would become the preferred choice for
Chemical Imaging. She cited the requirement of sample movement for pushbroom
systems and the limited throughput and excessive time consumption of filter based
systems as reasons for their diminished future use. On the other hand, it could be
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argued that with improvements in acquisition speed and spectral resolution,
pushbroom systems may find a place for in process monitoring of pharmaceutical
dosage forms on conveyor belt systems. At line pushbroom systems, in which tablets
would be diverted onto a moving stage for Chemical Imaging, would facilitate
analysis of a significantly higher number of tablets than traditional lab methods, albeit
not the desired complete assessment. Bellon-Maurel predicts that the market for NIRCI instrumentation will increase in the coming years, especially in the pharmaceutical
industry due to the FDA PAT initiative. She predicts that the price of imaging
spectrometers will fall, opening their way into routine pharmaceutical analysis. The
development of an average cost imager by combining microelectro-mechanical
systems (electrically programmable diffraction gratings) with spectrometers would
obviate the need for costly array detectors.

8.

Conclusions

The integration of spectroscopic and digital imaging in Chemical Imaging (CI)
produces position referenced spectra, which are valuable for the analysis of complex
multi-constituent samples. A major advantage of CI for the pharmaceutical industry is
its power to potentially assess all tablets in a production batch (not just a sample set),
thereby significantly reducing variability and risk. Moreover, its ability to spatially
localize drug constituents represents a vast improvement on average concentration
methods such as HPLC and MS. The non-destructive, rugged and flexible nature of
Chemical Imaging (CI) makes it an attractive PAT for identification of critical control
parameters that impact on finished product quality. Judging by the continuing
emphasis on process analytical technologies to provide accurate, rapid, nondestructive analysis of pharmaceutical processes it is likely that CI will be
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increasingly adopted for process monitoring and quality control in the pharmaceutical
industry as has been the case with NIR spectroscopy. Future innovations in CI
equipment manufacture are likely to depress purchase costs and encourage more
widespread utilisation of this emerging technology in the pharmaceutical sector.
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Table 1. Comparison of NIR spectroscopy (NIRS), Raman spectroscopy (RS) and
Chemical Imaging (CI).
Feature

NIRS

RS

Spatial information

CI

a

Spectral information

a

a

a

Multiconstituent information

a

a

a

Sensitivity to minor components
Tolerance to sample geometry
Quantitative information without having

a
a

a
a

to run separate calibration samples
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Table 2. Recent pharmaceutical applications of NIR Chemical Imaging
Configuration
Pushbroom
Staring imager

Application
Compositional information
Quality assessment
Process
related
information
Blend uniformity
Coating thickness
Counterfeit drug detection
Remote identification
High throughput analysis

Reference
[28], [29]
[20], [30]
[31], [32]
[33], [34]
[35]
[36], [37]
[38], [41]
[38], [39]
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Table 3. Recent pharmaceutical applications of Raman Chemical Imaging
Configuration
Staring Imager
Pushbroom
&
Staring Imager
Pushbroom

Application
Reference
Particle size estimation
[48]
Minor
component [22], [49]
detection
Tablet characterisation
Extraction of
Related Effects

[17], [29], [50], [51], [52], [53], [54]

Process [18]
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λ

Y

X
Pixel spectrum at (xi,yj)
Reflectance

Image plane at λi

Wavelength λ
(xi,yj)

λi

Fig. 1. Schematic representation of hyperspectral imaging hypercube showing the
relationship between spectral (λ) and spatial (X, Y) dimensions.
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Fig. 2. Typical components of a Chemical Imaging system
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Fig. 3. Schematic diagram of Chemical Image data analysis process
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Figure 4. Schematic of NIR Chemical Imaging blend monitor mounted to a Vblender.
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Fig. 5. Composite Raman image comparing data from two tablets with the same
overall composition but different formulation protocols.The image on the right is from
a tablet granulated in a single step, that on the left is from a tablet where the API was
first dissolved in binder and the resulting mass reground before being granulated. In
these images the positions where the spectra show the highest correlation with that
that of a sample having the required API and binder/excipient band intensities are
white/pink. Positions where there is poorer correlation are green/blue. (Image
courtesy of Perkin Elmer Inc)
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Fig. 6. Plot of the peak area of the strongest MDMA band (12376 nm) in the Raman
spectra of a seized ecstasy tablet recorded on an 8x8 grid with 10 µm spacing using a
Raman microscope. The inset shows typical spectra recorded in (a) the high-drug
(MDMA) region and (b) the low-drug (lactose) region [51] (Reprinted courtesy of the
Journal of Raman Spectroscopy).
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